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Increased vascular-endothelial growth factor A (VEGF-A) 
expression and response to angiogenesis inhibitor erlotinib in 
non-small-cell lung cancer (NSCLC) - Hint for a new predictive 
marker?
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Background: Non-small-cell lung cancer (NSCLC) is the most com-
mon cancer in the world and prognosis is poor. Recently, erlotinib, an 
epithelial growth factor receptor (EGF-R) tyrosine kinase inhibitor has 
shown to be effective in terms of survival in second/third-line chemo-
therapy. However, the overall response rate is about 9%. Somatic muta-
tions of the EGF-R gene or ampliﬁcations of the EGF-R gene seem to 
be associated with response to erlotinib.
Methods and Results: We report about a young non-smoking Cauca-
sian woman with metastastic NSCLC progressive to ﬁrst-line platin-
based combination therapy. She had a good partial response to erlotinb 
as second line therapy lasting over 6 months. By sequencing exons 
19-21 of the EGF-R gene and the K-RAS gene, there was no somatic 
mutation detectable in the tumour or in a liver metastasis. Additionally, 
using chromogenic in situ Hybridisation (CiSH) there was no EGF-R 
ampliﬁcation found in the tumour or metastasis. However, we found a 
VEGF-A mRNA overexpression in the primary lung tumour and liver 
metastasis in comparisson to normal lung epithilium. VEGF-A overex-
pression was conﬁrmed at the protein level by immunohistochemistry. 
Conclusions: These ﬁndings contribute to the hypothesis, that there 
might be an association between the EGF-R and VEGF pathways. Fur-
thermore, VEGF expression might be another marker for response to 
erlotinib therapy in NSCLC. To further analyse this potential predictive 
factor, VEGF expression should be studied systematically in responders 
to erlotinib therapy.
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MicroRNAs in human lung cancer and human lung embryogenesis
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Aim: To analyze if the miRNAs present in lung embryogenesis are also 
active in lung tumors and which are differentially expressed between 
tumor and normal lung tissue.
Methods: We studied by Real Time-PCR 18 mature miRNAs (let-7a 
family, cluster 17-92, mir-155, RNU6B, RNU66) in lung tissue from 
twelve 7-12-week human embryos and 36 human lung samples (18 
tumor and 18 normal). Data were analyzed with BRB Array tools and 
TIGR M-Viewer. 
Results: The hierarchical clustering showed four groups: E7-8 em-
bryos, E9-12 embryos, tumor and normal samples. Embryonic samples 
were closer to tumor samples. To determine common miRNAs during 
tumor and embryonic development, we analyzed the miRNAs differen-
tially expressed between tumor and embryonic tissues versus normal. 
miRNAs mir-17-5p, mir-106a, mir-19a, mir-25, mir-93 and mir-98 
were overexpressed in tumor and embryos samples and miRNAs let-
7a, let-7b, let-7c and let-7g were underexpressed compared to normal 
samples. 
We analyzed the miRNAs differentially expressed between tumor and 
normal samples and we found that mir-106a, 93, 17-5p, 25, mir-98 and 
mir-19a were signiﬁcantlly overexpressed and let7-a, let-7c, let-7g and 
let-7b were signiﬁcantlly underexpressed. These miRNAs allows to 
classify a sample as tumoral or normal.
Conclusions: Due to their similar expression miRNAs of cluster-17-92 
and members of let-7 family play a role during the normal lung and 
tumor development. These miRNAs may be a good targets for new 
therapeutics strategies. 
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Expression networks regulated by gene dosage in lung 
adenocarcinoma
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Background: Adenocarcinoma (AC) is the most common lung cancer 
cell type in many countries. Identiﬁcation of genes such as EGFR has 
demonstrated the importance of deﬁning primary pathway alterations 
for the development of new AC treatments. However, genes altered 
at the expression level may be a result of reactive changes through 
complicated regulation by other genes. Thus, genes whose expression 
is regulated by alterations in gene dosage (copy number) are attractive 
targets for therapeutic intervention as they likely represent the primary 
alterations in cancer development.
Methods: We integrated high resolution copy number proﬁles (whole 
genome SMRT array CGH) for 20 cell lines and 27 primary tumors, 
with Affymetrix [Cancer Cell 2006 Jul 10(1):39-50] and custom 
Agilent (tumors) expression data. The Mann Whitney U test was 
used to identify copy number regulated genes in both sample sets and 
genes identiﬁed in both cell lines and tumors were isolated for further 
analysis. Pathway based analysis and integration of publicly available 
survival study results [Nature Medicine 2002 Aug 8(8):816-24] were 
performed with Ingenuity Pathway Analysis software.
Results: Comparison of copy number and expression proﬁles in com-
plimentary sets of cell lines and primary tumour samples identiﬁed 458 
genes which appear to be causally regulated by copy number alteration 
in AC. Integration of our new ﬁndings with survival data correlated 
genes generated a striking overlap in the disruption of cellular pathway 
functions between the two data sets. These results can explain the 
disruption of survival correlated functions by primary copy number 
induced deregulation.
Conclusions: Integration of gene expression and copy number data de-
lineated genetic alterations that are correlated with outcome. The iden-
tiﬁed genes may serve as prognostic markers and therapeutic targets 
